Q

    Quanterix Corp (QTRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.67
    +0.03 (+1.14%)

    Market Cap: $126.27M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    54%(19/35)
    Avg Surprise
    +1.05%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.41
    Range$-0.42 - $-0.39
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.29+30.1%
    60d ago$-0.29+30.1%
    30d ago$-0.29+30.1%
    7d ago$-0.29+29.3%
    Current$-0.41
    Revenue Consensus
    $35M
    Range$33M - $36M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.21
    Range$0.21 - $0.21
    1 analysts
    Revenue Consensus
    $35M
    Range$33M - $36M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.21---
    Sep 26EST
    		-$-0.41---
    Jun 26
    Reported Aug 6
    		$-0.45$-0.56+19.64%Beat+4.3%
    Mar 26
    Reported May 6
    		$0.16N/A+125.81%Beat+130.2%
    Dec 25
    Reported Mar 2
    		$-0.47$-0.43-8.75%Miss-56.7%
    Sep 25
    Reported Nov 10
    		$-0.73$-0.53-37.74%Miss-231.8%
    Jun 25
    Reported Aug 7
    		$-0.47$-0.41-14.63%Miss-88.0%
    Mar 25
    Reported May 12
    		$-0.53$-0.43-23.26%Miss-103.8%
    Dec 24
    Reported Mar 17
    		$-0.30$-0.25-18.11%Miss+9.1%
    Sep 24
    Reported Nov 11
    		$-0.22$-0.23+4.35%Beat-4.8%
    Jun 24
    Reported Aug 8
    		$-0.25$-0.26+3.85%Beat-92.3%
    Mar 24
    Reported May 7
    		$-0.26$-0.31+16.13%Beat-85.7%
    Dec 23
    Reported Feb 29
    		$-0.33$-0.32-3.13%Miss+34.0%
    Sep 23
    Reported Nov 6
    		$-0.21$-0.40+47.50%Beat+47.5%
    Jun 23
    Reported Aug 7
    		$-0.13N/A+68.29%Beat+80.6%
    Mar 23
    Reported May 9
    		$-0.14N/A+63.16%Beat+71.4%
    Dec 22
    Reported Mar 6
    		$-0.50$-0.47-6.38%Miss+9.1%
    Sep 22
    Reported Nov 8
    		$-0.40$-0.44+9.09%Beat+7.0%
    Jun 22
    Reported Aug 8
    		$-0.67$-0.59-13.56%Miss-116.1%
    Mar 22
    Reported May 10
    		$-0.49$-0.61+19.67%Beat-69.0%
    Dec 21
    Reported Mar 1
    		$-0.55$-0.66+16.67%Beat-77.4%
    Sep 21
    Reported Nov 4
    		$-0.43$-0.33-30.30%Miss-65.4%
    Jun 21
    Reported Aug 5
    		$-0.31$-0.33+6.06%Beat+24.4%
    Mar 21
    Reported May 5
    		$-0.29$-0.34+14.71%Beat+23.7%
    Dec 20
    Reported Mar 2
    		$-0.31$-0.33+6.06%Beat+20.5%
    Sep 20
    Reported Nov 5
    		$-0.26$-0.42+38.10%Beat+23.5%
    Jun 20
    Reported Aug 4
    		$-0.41$-0.50+18.00%Beat+10.9%
    Mar 20
    Reported May 5
    		$-0.38$-0.41+7.32%Beat+9.5%
    Dec 19
    Reported Mar 13
    		$-0.39$-0.43+9.30%Beat+0.0%
    Sep 19
    Reported Nov 8
    		$-0.34$-0.44+22.73%Beat+2.9%
    Jun 19
    Reported Aug 6
    		$-0.46$-0.42-9.52%Miss-35.3%
    Mar 19
    Reported May 10
    		$-0.42$-0.40-5.00%Miss-27.3%
    Dec 18
    Reported Mar 18
    		$-0.39$-0.31-25.81%Miss+63.2%
    Sep 18
    Reported Nov 7
    		$-0.35$-0.31-12.90%Miss+53.3%
    Jun 18
    Reported Aug 10
    		$-0.34$-0.29-17.24%Miss+8.1%
    Mar 18
    Reported May 15
    		$-0.33$-0.27-22.22%Miss-
    Dec 17
    Reported Mar 19
    		$-1.06$-0.32-231.25%Miss-
    Sep 17
    Reported Dec 15
    		$-0.75$0.00N/AMiss-
    Jun 17
    Reported Jul 21
    		$-0.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.79EV/EBITDA-1.49x
    Price/FCF-1.54xFCF Yield-65.01%
    Profitability
    Profit Margin-80.20%Operating Margin-68.40%
    ROE-46.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage37.00x
    Current Ratio3.40xQuick Ratio2.45x
    Trading Statistics
    Beta1.07Avg Volume841.18K
    52-Week High$8.7752-Week Low$2.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.80
    SMA 20$2.98
    SMA 50$3.53
    SMA 200$4.68
    EMA 10$2.78
    EMA 20$2.96
    EMA 50$3.27
    EMA 200$4.23

    MACD

    Line: -0.24Signal: -0.23Hist: -0.01

    ADX

    ADX: 22.5+DI: 18.3-DI: 33.0

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down40.0
    PSAR$3.55

    Bollinger Bands

    Upper Band$3.92
    Lower Band$2.04
    %B Position6287%(Upper)
    Band Width0.33

    RSI (14-Day)

    Neutral
    40.7

    Momentum Oscillators

    Stoch %K33.9
    Stoch %D34.7
    Williams %R-74.4
    ROC (10d)-8.6%
    Momentum-0.25
    CCI (20d)-66.6
    MFI (14d)55.6

    Volatility Measures

    ATR (14d)$0.28(10.3%)
    StdDev (20d)0.47
    Hist Vol176.9%(High)

    Volume Flow

    VWAP$2.63
    OBV-15.3M
    AD Line-5.6M
    CMF (20d)0.163

    Volume Metrics

    Avg Vol (20d)864.1K
    Vol Ratio0.5x(Low)
    VWMA (20d)$2.80

    Pivot Points

    R3$2.77
    R2$2.72
    R1$2.68
    Pivot Point$2.63
    S1$2.59
    S2$2.54
    S3$2.50

    Advanced Oscillators

    TSI-17.15
    Ultimate Osc36.0
    KST-245.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.91M$36.41M$43.85M$40.23M$24.48M$30.33M$35.16M$35.81M$34.38M$32.07M$31.55M$31.56M
    Cost of Revenue$20.23M$20.85M$23.82M$23.03M$14.47M$15.49M$12.99M$15.66M$12.15M$13.52M$12.14M$12.15M
    Gross Profit$12.67M$15.57M$20.04M$17.21M$10.00M$14.84M$22.17M$20.15M$22.23M$18.55M$19.41M$19.41M
    Operating Expenses$62.18M$56.93M$44.85M$54.47M$47.10M$41.20M$36.94M$31.90M$33.18M$33.70M$33.02M$32.22M
    R&D$7.82M$7.32M$8.80M$8.01M$9.08M$10.04M$8.07M$8.10M$8.17M$6.74M$7.21M$7.74M
    SG&A$27.35M$29.77M$35.14M$39.06M$30.35M$31.17M$28.59M$22.91M$24.08M$26.04M$23.47M$23.55M
    Operating Income$-49,431,000$-41,362,000$-24,751,000$-37,325,000$-37,100,000$-26,366,000$-14,769,000$-11,748,000$-10,942,000$-15,157,000$-13,617,000$-12,808,000
    Interest Income$761,000$0$0$0$2.69M$0$0$0$0$0$0$0
    Interest Expense$0$-892,000$-1,160,000$-1,448,000$0$-3,267,000$-3,491,000$-3,535,000$-3,681,000$-3,948,000$-4,319,000$-4,185,000
    Income Before Tax$-48,988,000$-17,548,000$-22,771,000$-35,997,000$-30,086,000$-23,417,000$-11,636,000$-8,208,000$-7,270,000$-10,983,000$-8,672,000$-6,513,000
    Income Tax Expense$-54,000$-7,000$345,000$-2,480,000$-73,000$-2,913,000$-8,000$145,000$117,000$180,000$141,000$203,000
    Net Income$-48,934,000$-17,541,000$-23,116,000$-33,517,000$-30,013,000$-20,504,000$-11,628,000$-8,353,000$-7,387,000$-11,163,000$-8,813,000$-6,716,000
    EBITDA$-42,784,000$-12,190,000$-16,851,000$-31,148,000$-31,078,000$-24,914,000$-14,398,000$-11,294,000$-10,950,000$-14,587,000$-11,536,000$-9,674,000
    EBIT$-49,670,000$-18,440,000$-23,873,000$-37,503,000$-32,778,000$-26,684,000$-15,127,000$-11,743,000$-10,951,000$-14,931,000$-12,991,000$-10,698,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QTRX

    Government Contracts

    Gov Obligations (TTM)
    $180314
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    8
    New Awards (TTM)
    3
    Avg Remaining Term
    13.9 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24625P1494Department of Veterans AffairsDepartment of Veterans Affairs$95348Aug 30, 2025
    36C25925P1065Department of Veterans AffairsDepartment of Veterans Affairs$81850Sep 15, 2025
    75N94026P00081Department of Health and Human ServicesNational Institutes of Health$12437Jan 14, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Bruker Corporation Executive is Named Finance Chief at Quanterix

    Quanterix Corporation has appointed Jason Faessler, formerly of Bruker Corporation, as its new chief financial officer. Faessler's extensive experience in finance leadership within the life science tools industry is expected to be crucial for Quanterix's future growth. He previously held senior financial roles at PAREXEL, EMC (now Dell), and Harvard Business Publishing.

    Medical Product Outsourcing•8/21/26•
    Bullish

    Quanterix (QTRX) director adds 3,955 shares via RSU vest

    Quanterix Corp (QTRX) director Jeffrey Thomas Elliott converted 3,955 restricted stock units (RSUs) into common stock on August 19, 2026, increasing his direct common stock holdings to 15,345 shares. He still holds 4,075 RSUs from an original grant of 11,985 RSUs issued on August 19, 2024, which vest over three years. This transaction was an exercise/conversion of a derivative security and not an open-market purchase or sale.

    Stock Titan•8/20/26•
    Neutral

    Quest Diagnostics Executive Recruited to Quanterix’s Senior Management Team

    Quanterix Corporation has appointed Geoff Albrecht, formerly of Quest Diagnostics, as Senior Vice President and General Manager of Diagnostics. Albrecht will lead Quanterix’s Diagnostics strategy, focusing initially on Alzheimer's Disease Diagnostics, and will be responsible for scaling the company's diagnostics portfolio into a significant revenue driver. This hire emphasizes Quanterix's commitment to making diagnostics a core part of its future growth, leveraging Albrecht's 25 years of commercial leadership experience.

    Medical Product Outsourcing•8/20/26•
    Bullish

    Quanterix (QTRX) director now holds 162,401 shares

    Quanterix Corp (QTRX) director William P. Donnelly reported the vesting and conversion of 2,802 restricted stock units (RSUs) into common stock on August 17, 2026. Following this transaction, Donnelly directly holds 162,401 shares of Quanterix common stock. The RSUs were originally granted on August 17, 2023, with a three-year vesting schedule.

    Stock Titan•8/19/26•
    Neutral

    Quanterix (QTRX) CCO files initial ownership report with no shares

    James Edward Gute Jr., Chief Commercial Officer of Quanterix Corp (QTRX), has filed an initial statement of beneficial ownership of securities (Form 3) with no current reportable holdings or transactions in Quanterix Corp securities. This filing indicates that as of the report date, he does not beneficially own any shares of the company, serving as an initial inventory sheet for his insider status. The document also details the specifics of the Form 3 filing, including the date of event and reporting person's information.

    Stock Titan•8/19/26•
    Neutral

    Frequently Asked Questions About QTRX

    Does QTRX pay dividends?
    Quanterix Corp (QTRX) does not currently pay a regular dividend.
    What is QTRX's market cap?
    Quanterix Corp (QTRX) has a market capitalization of $126.27M with a current stock price of $2.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In